36663
2,4′-DDE solution
100 μg/mL in methanol, PESTANAL®, analytical standard
Synonym(s):
2-(2-Chlorophenyl)-2-(4-chlorophenyl)-1,1-dichloroethene solution
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C14H8Cl4
CAS Number:
Molecular Weight:
318.03
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
EC Number:
200-659-6
Beilstein/REAXYS Number:
1977640
MDL number:
grade
analytical standard
Quality Level
product line
PESTANAL®
shelf life
limited shelf life, expiry date on the label
concentration
100 μg/mL in methanol
technique(s)
HPLC: suitable, gas chromatography (GC): suitable
application(s)
agriculture
format
single component solution
storage temp.
2-8°C
SMILES string
Clc1ccc(cc1)\C(=C(\Cl)Cl)c2ccccc2Cl
InChI
1S/C14H8Cl4/c15-10-7-5-9(6-8-10)13(14(17)18)11-3-1-2-4-12(11)16/h1-8H
InChI key
ZDYJWDIWLRZXDB-UHFFFAOYSA-N
Application
Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.
Legal Information
PESTANAL is a registered trademark of Merck KGaA, Darmstadt, Germany
signalword
Danger
Hazard Classifications
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
target_organs
Eyes
Storage Class
3 - Flammable liquids
wgk
WGK 1
flash_point_f
51.8 °F
flash_point_c
11 °C
ppe
Eyeshields, Faceshields, Gloves
Regulatory Information
危险化学品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Ilse G Hermsen et al.
The Journal of clinical endocrinology and metabolism, 96(6), 1844-1851 (2011-04-08)
In patients with adrenocortical carcinoma (ACC) mitotane activity has been suggested to depend on plasma levels 14 mg/liter or greater and metabolite formation. The study was performed to confirm the correlation of the currently used mitotane (o,p'DDD) threshold of 14
Anna A Kasperlik-Zaluska et al.
Journal of experimental therapeutics & oncology, 5(2), 125-132 (2006-02-14)
Our study aimed at evaluation of the relations between the plasma levels of mitotane (o,p'-DDD) and its metabolites, o,p'-DDA and o,p'-DDE, and the efficacy of Mitotane therapy during a long-term follow-up. Eighteen patients, aged 11 to 70 years, were included
R Benecke et al.
European journal of clinical pharmacology, 41(3), 259-261 (1991-01-01)
Mitotane (o,p'-DDD) can be used for the treatment of various adrenocortical diseases such as Cushing's syndrome, but the usual doses of 6-8 g per day are often associated with severe adverse effects. This paper reports the results of much lower
Global Trade Item Number
| SKU | GTIN |
|---|---|
| W366005-100G-K | 04061838093967 |
| 44191-100MG | 04061832282282 |
| W366005-1KG-K | 04061838183071 |
| W366005-25G-K | 04061838249289 |
| W366005-SAMPLE-K | 04061838258069 |
| 36663-2ML | 04061831826371 |